Up­dat­ed: Roche pulls PD-L1 block­buster's ac­cel­er­at­ed ap­proval in blad­der can­cer

The FDA’s cleanup on aisle ac­cel­er­at­ed ap­proval con­tin­ued this morn­ing as Roche an­nounced it would vol­un­tar­i­ly pull from the mar­ket an in­di­ca­tion for its block­buster can­cer im­munother­a­py Tecen­triq for adult pa­tients with cer­tain types of blad­der or uri­nary tract can­cer.

Roche unit Genen­tech said it made this de­ci­sion fol­low­ing a failed con­fir­ma­to­ry tri­al, and in ac­cor­dance with the re­quire­ments of the FDA’s ac­cel­er­at­ed ap­proval pro­gram, which has been in re­vamp mode, par­tic­u­lar­ly in on­col­o­gy, where many ac­cel­er­at­ed ap­provals have been grant­ed in re­cent years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER